Estrogen Receptor Positive Breast Cancer Completed Phase 2 Trials for Tamoxifen (DB00675)

Also known as: Oestrogen receptor positive breast cancer

IndicationStatusPhase
DBCOND0049177 (Estrogen Receptor Positive Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02988986TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast CancerTreatment
NCT00003199Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerTreatment
NCT00194779Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By SurgeryTreatment
NCT009527314-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in SituTreatment